Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NMT2 | O60551 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442528 | 1.00 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL31442451 | 0.91 | SMN1; SMN2 (0.81) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL31442597 | 0.91 | SMN1; SMN2 (0.81) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL3325758 | 0.88 | SMN1; SMN2 (0.77) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL15976546 | 0.87 | ALDH1A1 (1.00) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL14463535 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL3322903 | 0.85 | FABP4 (0.73) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL12498023 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL10256511 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL31442541 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753724-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | SIRCAR JAGADISH C | 2006-01-12 | — | — | US | disclosed |
| WO-2005123686-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | LDLR, NPC1L1, CETP | SMN1; SMN2 4780/4885LMNA 1144/4885MEN1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.